GSK 1247303

Drug Profile

GSK 1247303

Alternative Names: 1247303; S-247303

Latest Information Update: 06 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi - GlaxoSmithKline (JV)
  • Developer ViiV Healthcare
  • Class Antiretrovirals
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 06 Nov 2012 No development reported - Phase-II for HIV infections in USA (PO)
  • 31 Oct 2012 ViiV Healthcare acquires exclusive global rights to the assets of the joint venture Shionogi-ViiV Healthcare LLC, including HIV integrase inhibitors
  • 01 Jul 2010 Phase-II clinical trials in HIV infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top